National, Multi-center, Prospective, and Retrospective Cohort Study.
NCT ID: NCT04520204
Last Updated: 2022-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
10000 participants
OBSERVATIONAL
2020-10-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Key goals:
• Obtaining real-world evidence on the diagnosis and treatment of AIM in Russian hospitals, including both long- and short-term findings and outcomes (i.e. during hospitalization,
and 6-12 months after the diagnosis establishment).
* Evaluation of the applied approaches to the management of AIM patients for compliance with the clinical recommendations across various hospitals, with a breakdown by equipment status;
* Assessment of patients' treatment adherence after 6 and 12 months.
The expected project duration is 3 years. The study subjects will be recruited during the first 24 months unless the investigators decide to terminate or extend the study period. The period of observation for each patient is 6 to 12 months. The project involves retrospective and prospective collection of information from medical records. All patient data shall be recorded by the Investigator into an approved electronic case report form (eCRF).
Recruitment period: 2020-2022. Expected number of subjects: 10,000.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow
NCT03654157
Coronary Heart Disease Complicated With Ischemic Mitral Regurgitation in China
NCT07230756
Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Insufficiency.
NCT02054221
Screening of Valvular Heart Disease Using Single-channel Electrocardiogram
NCT07099417
Stress Echo for Ischemic Mitral Valve Surgery
NCT04023058
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The partner inpatient hospitals will provide data on every patient with known acute myocardial infarction (I21) admitted between days 1 and 10 of each month during the recruitment period.The Russian Registry of Acute Myocardial Infarction study is an independent study initiated by the investigators;
For every engaged hospital (medical center) the investigators will designate a 2-3 person task team, including a Team Leader;
The participants shall be kept informed and coordinated via email and messengers. The website of the Russian Society of Emergency Cardiology.
The study will be hosted by the CRM Quinta® platform.
Administration, data entry monitoring, and statistical processing will be carried out by Aston Consulting (a certified personal data operator.)
AO Aston Consulting has a license for storage and processing of personal data in accordance with the applicable legislation.
PATIENTS.
INCLUSION CRITERIA
1\. Diagnosed acute ST-elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI) (ICD 10 I21 ); the diagnosis is established based on the Fourth Universal Definition of Myocardial Infarction Guidelines 2018 .
EXCLUSION CRITERIA
1\. A patient or his/her legal representative did not sign IC.
STUDY ASSESSMENTS
The following information will be collected and entered into CRF: Full name
Residential address
Phone number of patients or their legal representatives' Demographic profile. Weight, height
Social status (education, job title, occupation status)
Co-morbidities
Clinical signs and symptoms
Drug therapy.
Clinical outcomes during the hospital stay.
Drug therapy and clinical outcomes in 6 and 12 months after the diagnosis establishment.
Hospitals wishing to join the study must contact any of the project coordinators and complete the Participation questionnaire (Appendix 4).
The Registry enrolment process starts in 2020 and will continue for 24 months. The hospitals that will not be able to start the enrolment in 2020 will have the chance to do it before December 31, 2022, and perform the follow-up monitoring for the next 12 months.
At the moment of the enrolment, the patient's data are to be entered into the online database. Any new data that might appear during the hospital stay will be successively or immediately entered into the database at the moment of the patient's death/discharge. The data received during an in-person or a phone contact 6 or 12 months after the enrolment will also be entered into the database.
Shall the initiators have any questions regarding the entered data, they will ask the participants to elaborate, clarify, or correct the data.
If the patient dies before the enrolment to the study, his/her data shall be entered into the database retrospectively.
The patients (or their legal representatives) enrolled to the Registry must be kept informed about the inclusion in this observational program and give their written consent for participation (patients who died or are otherwise unable to sign the consent to the processing of personal data will be enrolled on a de-identified basis.)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
The diagnosed patient was admitted to the hospital between days 1 and 10 of the current mont.
Exclusion Criteria
\-
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Healthy Future
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pevzner
Role: PRINCIPAL_INVESTIGATOR
Myasnikov Institute of Clinical Cardiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Federal State Budgetary Institution NATIONAL MEDICAL CENTER CARDIOLOGY RESEARCH CENTER Ministry of Health of the Russian Federation
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMI 05.2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.